Whalesbook
Marengo Plans ₹5,000 Cr Valuation in Stake Sale
Marengo Asia Hospitals plans to raise ₹500 crore by selling a 10% stake, targeting a ₹5,000 crore valuation. The company seeks external capital, supported by existing investors Samara Capital, the Godrej Group family office, and the Havells India promoter family office. Marengo reported ₹1,200 crore in revenue for FY25-26. Based on the proposed valuation, this represents a Price-to-Sales (P/S) ratio of about 4.17x. The hospital chain has appointed Avendus Capital to manage the transaction, aiming to attract sovereign wealth funds and specialized healthcare investors.
Expansion Through Acquisitions and International Reach
Marengo's growth relies on an aggregation strategy, acquiring multiple healthcare facilities since October 2020. The company now operates eight hospitals with 2,500 beds across India's National Capital Region, Gujarat, and Rajasthan. Marengo also has a presence in Saudi Arabia, a market undergoing significant healthcare investment and privatization as part of its Vision 2030 plan. The Saudi healthcare sector is valued at about $67 billion in 2024 and aims for 65% private sector participation by 2030, needing an estimated 27,000 more hospital beds by then. Marengo plans further acquisitions in Rajasthan and Maharashtra, supporting its expansion in India and potentially abroad.
Industry Valuations and Investment Trends
The Indian healthcare sector is attracting substantial investment, with hospitals alone receiving about ₹43,310 crore from private equity between 2022 and 2024. Major listed hospital groups like Apollo Hospitals and Max Healthcare trade at P/E ratios between 59-63x, while Fortis Healthcare's P/E is around 68x. These larger companies, such as Max Healthcare with ₹5,437 crore revenue in FY24, typically trade at enterprise value to EBITDA multiples of 30-35x. Marengo's target valuation seems high compared to its current revenue scale, especially against the EBITDA multiples of larger, listed competitors. Private equity investors are focusing on scalable platforms and consolidating smaller assets for growth.
Scrutiny on Valuation and Potential Risks
Marengo's proposed ₹5,000 crore valuation invites scrutiny. While revenues were ₹1,200 crore in FY25-26, profitability metrics like EBITDA margins are not public, making direct comparison difficult. Industry reports suggest listed hospital chains trade at EV/EBITDA multiples of 30-35x, indicating Marengo's valuation implies significant expected EBITDA or a premium on its current scale. The aggregation strategy, while promoting rapid expansion, carries risks of integration issues and quality inconsistencies across acquired facilities, potentially affecting occupancy. Operating in Saudi Arabia offers growth but also brings geopolitical and regulatory complexities. India's healthcare sector faces regulatory risks, such as potential price caps on procedures and devices, which could impact margins. High execution risk exists as Marengo integrates new facilities and expands.
Outlook for Growth and Challenges Ahead
The funds raised are expected to accelerate Marengo's growth, enabling further acquisitions and expansion into regions like Rajasthan and Maharashtra. India's healthcare sector is forecast to grow at a 12% CAGR over the next three to five years, driven by rising insurance coverage, a larger middle class, and more chronic diseases. However, the sector also faces challenges, including potential capacity expansion outpacing absorption and complex regulations. Investors will watch how Marengo translates its valuation and expansion plans into sustained profits and market leadership in this competitive landscape.